Le Lézard
Classified in: Health
Subjects: NPT, TDS, AVO

US Representative Carolyn Maloney to Headline MRF Advocacy Days Plenary


WASHINGTON, March 6, 2022 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) will host nearly 100 advocates during the all-virtual MRF Advocacy Days held March 7-11, 2022. U.S. Representative Carolyn B. Maloney (NY-12) will be featured as the program plenary speaker on March 7th.

Advocacy Days is the largest annual melanoma advocacy event convening nationwide participants to engage with federal lawmakers on key policy areas impacting the melanoma community such as research, education, access and prevention. In 2022, advocates will urge Congress for continued funding of $40 million for Department of Defense (DoD) funded melanoma research through the Congressionally Directed Melanoma Research Program (CDMRP). These funds will support research ranging from prevention to metastatic treatment for all melanoma patients, including rare subtypes.    

"I am honored to participate in the MRF's 2022 Advocacy Days program alongside truly inspirational melanoma advocates," says Rep. Maloney. "Meaningful patient and caregiver stories can have a lasting impact on the legislative process and help drive the federal government's support for critical research with the ultimate goal of ending melanoma."

Rep. Maloney is a longtime supporter of the MRF and the melanoma community, introducing the 2007 Tanning Accountability and Notification (TAN) act requiring tanning bed labels to provide sufficient information about the risks associated with indoor tanning. Her Advocacy Days plenary will highlight the crucial role that advocates have in improving outcomes for melanoma patients and her commitment to ensuring access to skin cancer prevention for all Americans.

For questions about the event or the MRF's Advocacy program, please contact [email protected].

The MRF thanks our 2022 Advocacy Days sponsors: Amgen, Bristol Myers Squibb, Genentech, IOVANCE, Merck, and Pfizer.

About the Melanoma Research Foundation?

The Melanoma Research Foundation (MRF) is the largest independent organization devoted to melanoma. Committed to the support of medical research to develop effective treatments and eventually a cure for melanoma, the MRF also educates patients and physicians about the prevention, diagnosis and treatment of melanoma. The MRF is a dedicated advocate for the melanoma community, helping to raise awareness of this disease and the need for a cure.?The MRF's website is the premier source for melanoma information seekers. More information is available at http://www.melanoma.org. Find the MRF on Facebook, Twitter, LinkedIn and Instagram.??

Media Contact

James Merrick, MPA

Chief Communications and Marketing Officer

[email protected]

Media Contact

James Merrick, Melanoma Research Foundation, +1 (202) 579-3450, [email protected]

Twitter

 

SOURCE Melanoma Research Foundation


These press releases may also interest you

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...

3 jui 2024
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...



News published on and distributed by: